Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting Septembe...(ting results and other risks and uncerta...),Health

Date:9/6/2007

ting results and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission (SEC), such as the company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the company

as of the date hereof, and, subject to any applicable law to the contrary, the company assumes no obligation to update any forward-looking statements.

PAR PHARMACEUTICAL COMPANIES, INC.

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2006 AND 2005

(In Thousands, Except Share Data)

December 31, December 31,

ASSETS 2006 2005

Current assets:

Cash and cash equivalents $120,991 $93,477

Available for sale debt and

marketable equity securities 92,120 103,066

Accounts receivable, net 94,784 62,362

Inventories 106,322 96,393

Prepaid expenses and other current assets 15,833 18,759

Deferred income tax assets 72,105 69,256

Income taxes receivable 12,422 18,859

Assets held for sale - 1,944

Total current assets 514,577 464,116

Property, plant and equipment, at cost

less accumulated depreciation and

amortization 89,155 87,570

Available for sale debt securities 7,652 3,741

Investment in joint venture 5,29
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored